SLC5A2 and type 2 diabetes mellitus: Recently, Mazidi et al. undertook a systematic review and meta-analysis of 43 randomized control trials (dapagliflozin: 22 trials; canagliflozin: 14 trials; empagliflozin: 4 trials; remogliflozin: 2 trials; pragliflozin: 1 trial) to determine the effect of SGLT2 inhibitors on BP among individuals with T2DM [104].